AAP
CGEM icon

Arax Advisory Partners’s Cullinan Oncology CGEM Stock Holding History

Arax Advisory Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8K Buy
2,625
+2,275
+650% +$33.8K ﹤0.01% 3296
2026
Q1 		$4.97K Buy
350
+178
+103% +$2.29K ﹤0.01% 2783
2025
Q4 		$1.78K Sell
172
-1,268
-88% -$11.4K ﹤0.01% 3304
2025
Q3 		$8.54K Buy
+1,440
New +$10.5K ﹤0.01% 2667
2024
Q4 		– Sell
-7
Closed -$118 – 2485
2024
Q3 		$118 Hold
7
– – ﹤0.01% 2549
2024
Q2 		$123 Buy
+7
New +$149 ﹤0.01% 2477

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Arax Advisory Partners's CGEM Position: Q2 2026 in Review

Arax Advisory Partners increased its Cullinan Oncology (CGEM) stake by 650% in Q2 2026, buying an estimated $33.8K and bringing the position to 2,625 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3296.

Arax Advisory Partners first reported a position in CGEM in Q2 2024 and has held it in 6 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Arax Advisory Partners held 2,625 shares of Cullinan Oncology worth $47.8K as of Q2 2026.
  • Arax Advisory Partners bought 2,275 Cullinan Oncology shares in Q2 2026, an estimated $33.8K.
  • Cullinan Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3296 holding.
  • Arax Advisory Partners first reported a position in Cullinan Oncology in Q2 2024 and has held it in 6 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.